In a report released yesterday, Thomas Shrader from BTIG maintained a Buy rating on Inmune Bio (INMB – Research Report), with a price target of $21.00.
Thomas Shrader has given his Buy rating due to a combination of factors that highlight Inmune Bio’s promising approach in Alzheimer’s treatment. The company’s Xpro drug is designed to target inflammation in the brain, a key factor in Alzheimer’s disease progression, and is currently undergoing a significant Phase 2b trial. The trial’s results are anticipated soon, with the company employing an enrichment strategy to select patients with systemic inflammation, which is believed to correlate with central nervous system inflammation.
Additionally, Inmune Bio has introduced the EMACC test, a novel evaluation tool that is more sensitive to cognitive changes in early-stage Alzheimer’s patients compared to traditional methods. This approach is expected to provide a clearer assessment of Xpro’s efficacy. The company’s financial position, with a reported net loss and cash reserves, also supports the potential for growth, making the stock an attractive buy according to Shrader’s analysis.
In another report released on March 31, Maxim Group also maintained a Buy rating on the stock with a $30.00 price target.